Member Info for chester18

Hi Knowlesi

Ok lets just presume for one minute that we could raise that amount.

So would that be enough cash to see us through to Phase 2 data fully collected and ready to partner Phase 3 ?

or is that too much money as we don't need that much ?

Chester

If we were totally unsuccessful in being awarded funds to build a 2nd Gen vaccine (which I would find very hard to accept) we need to get back to concentrating on the cancer trials as soon as possible.

My thoughts turn to raising the cash to support those phase 1 and 2 trials.

A 5p open offer for 300,000,000 shares would raise £15,000,000.

Is that enough money to enable Scancell to collect all necessary positive data, ready to partner the phase 3 studies?

Chester.

But it could be a day of announcements. Commitments to projects etc etc....

Scancell does seem to have gone quiet again, so fingers crossed that we hear some good news by Friday...

Chester.

Morning Ray

In what way is Scancell taking part.
I've looked at the Sclp website and there is nothing listed about it.
Are we just signed on or actually presenting?

Chester.

Did someone post that Scancell are taking part in this online global conference on Thursday?

Chester.

Hi Andy-Scott

GGP is a gold exploration company, who own a prospect called Havieron.
Having hit good gold mineralisation Newcrest Mining agreed a Joint Venture. Newcrest because of their own needs have blitzed through 2 to 3 years development in just over 12 months and are committed to achieving a Maiden Resource Estimate around September / October 2020 and the licences to start a Decline towards the mineralisation in early 2021.
Due to the use of public Satellite images this board is fully aware of each move by the 9 drilling rigs currently employed on site.
The potential gold in terms of the millions of ounces has grown and grown and grown. The word in the street is that this could be an extraordinary huge and very mineable resource. We are due a further update on the quality of drill cores by the 15th June and a Newcrest quarterly report by the end of July. The last seven drill core reports have been exceptional and the way Newcrest are continuing to press the ground teams to 24/7 there is no sign that reports 8, 9 or 10 will be any different.

So what is expected over the next 2, 4 and 6 months is just more of the same, plus the MRE will define the project making it irresistible to Institutional Investors.

I hope to gives you enough to go on..

ATB
Chester.

In my opinion today's news will be lost on many hundreds of participants in the PrimaryBid shares sale.

All they saw was a 75% discount to the traded price on that day and will exit the stock at any price above 0.3p (20% profit).

That's just my humble take on the situation, it will be interesting to see where we are, price wise, next Tuesday after the General Meeting, the Vote and we've seen the 2019 year end report.

Once the extra 5,848,000,000 shares hit the market next Wednesday the volumes of both buys and sells will be massive.

Anyway its all conjecture until the day..

Chester.

That is excellent news on OrthoPure XT it is a fantastic addition to the product range and has taken a good 3 - 4 years to see it pass through surgical trials and then the time to prove its equal to the normal harvesting procedure. Not seen any data on comparison recovery times from the surgery but OrthoPure XT saves on having to have a second surgical site so its a win, win.
That's another growth area for next year.

Chester.

TheOldBee, I totally concur,

Definitely good to have knowledgeable members of the discussion board, especially ones with insight into the value of TRX's current and future products.

So welcome aboard enteleon...

Chester.

I think an unfortunate truth is that many people bought the PrimaryBid shares without really knowing or understanding where TRX could be in the future. Their one and only aim is to turn a profit. Many will see 20% profit as time to leave. That's 0.3p and so if the buy price gets that low I will add some shares.

To go negative to the 0.25p would've a great surprise. As has already been muted, a positive RNS from the company could have a good effect on the price.

It is going to be very interesting to see where we are by this Friday.

Certainly not a boring share at the moment, its cost some of us but it's not boring......

Chester.

Thanks Ray,

So news this week then........!!

Seriously though, it would be good to hear an update from them one month on. We also hit 9 months into the first AvidiMab collaboration this coming week. News on the status of the other trials could also be quite close.

Chester.

Morning Inanaco

Thank you for the link, I read two thirds and my brain began to melt. My original enquiry as to where we may be with Covidity was to understand how Scancell could build the vaccine so quickly and then use mouse models to test the results.

Having read as much as possible of that link, I've now got a very vague understanding that it's a case of taking the bulk mechanism of Immunobody and adapting it to the CV-19 Spike + protein to gain greater binding and therefore a more effective destruction of the virus.

Am I now following the process more clearly?

Could Scancell be well on their way to demonstrating the effectiveness and efficacy in mouse models and will they test in human blood or even humanized mice models as they do with the cancer trials?

Questions, questions, but I feel that I would like to gain a better understanding of the processes of build the most effective vaccine model.

Chester.

Crumbs and Rats, thank you,

I didn't realise that they had already put it all together. I presumed that it would take alot more time to put the SCIB part to the Covidity part and also select the correct antibodies.

So does this mean that they will be testing different iterations of the drug or would they know exactly what mix they needed prior to moving onto the mice?

Chester.

I'm presuming that the whole Corvidity team are pulling together all the data necessary to gain UK Government funding. So considering the need to demonstrate safety and validity to win that funding,

'just how far along can we be after about 30 days' ?

Can we be ready to test in mice ?

Also, how much lab time will it take if we're running mice models to produce that data ?

Would really appreciate it if anyone can expand on those questions .... thanks

Chester.

If that vaccine proves to be a whimp that placing is akin to commercial piracy.

Chester.

Hi NK and welcome to the board,

The thing is with TRX it's always been about the Products, the IP, the Patents, the potential New Product Pipeline and the Approvals in the USA and Europe.
The market for Tissue Regenerative products and devices is already huge and growing year on year.

TRX would have grown gross sales year on year without the Woodford Investments injection of cash. With that investment they were, let's say, persuaded to buy CellRight, which instantly gave them a US presence plus £5m more turnover and it all looked good until Woodfords demise.
Then without the fairy godfather the financial overreach took its toll.

So I'm hopefull that both your goodself and I will think very differently in 12 / 18 months time because the road ahead is now quite straightforward.

If the current management mess up the next two or three big steps forward they really will be lacklustre morons.

The technology is everything, they are not competing they are accquiring new ground by converting more and more surgeons to their range of products, and once used the surgeons do not want anything else.

Other than organic growth over the next 2 to 5 years the only other factor would be a buyout by a much bigger player but only when they have the company growing and making good returns on investment.

So as you say I'm not giving up on them just being realistic that the decent return we all wanted will now depend on how well the BOD perform over the next year and a half, they don't have to do anything special just guide the ship forward.

Chester.

Having been well and truly kicked in the nether region, I have had to reassess my goals and aspirations for TRX.

On June 10th there will be a lot of the new shares owned by people who will take 20% or 30% profit rather than sit on their shares for 6 months. TRX may attempt to soften the churn by putting out a positive RNS but I just don't see us speeding back up to 1p in the first month or so.

5,900,000,000 new shares is a lot to digest by the market. It will settle down eventually as the company moves forward and announce future good news RNS'es. I'm now looking at 12 to 18 months to see the beginnings of the real value of this cash injection. No debts, no monthly interest repayments and the new lab facilities fully operational.

Like a few others I will buy a few more shares if the price goes anywhere near .3p

ATB
Chester.

This 'never having attracted a deal' thing is something that has really troubled and baffled me. With all the science knowledge on this board and understanding of what Scancell have achieved makes it unfathomable to us that a larger Pharma or Biotech company have not seen the same potential.

So why is it ??

I'm not sure that when interest did returned to Cancer Vaccines that SCIB1 with its Electroploration was the most attractive platform. Plus Ichors Trigrid device was more or less the prototype that's why we lost two years waiting for the FDA to approve the 'Mark 2' version.

It's also why Lindy and co, saw Nanoparticles as the way forward with SCIB2.

We may one day become aware of what approaches have been made to Scancell. We may well have batted away many low ball offers and as Cliff Holloway has said in his presentations when talking about future possibilities of deals "it's all about the data".

My guess is that our BOD do know what the potential worth of Scancells science and they have been very diligent in wrapping strong, wide ranging 'Patent Protection' around all the platforms.

But for some really bad luck and timing we are probably two years behind on SCIB1 but as Innan says, the science has not stopped over that period, we improve Modi1 and brought AvidiMad into the world.

Patience is a virtue they say but it is also a necessity when investing in an R&D Biotech company.

This current 'Covidity' could be a pivotal key to attracting the right kind of interest.

Chester.

So the other trades of 6.52 , 6.5 and 6.55 are all buys.

The MMs like to mess with the spread to create whatever illusion they reckon will cause more business.

'Sneaky Blighters'

Chester.

Hi Dickpuller

Just to keep the record straight that 103,098 was my buy.

Chester.